RBC Capital Markets has reiterated an Outperform rating on Glencore PLC, setting a 600p price target that suggests a 23% gain from the current price of about 513.8p. The broker favors Glencore due to its lack of iron ore exposure and strong coal earnings, alongside potential restructuring such as a coal spin-out or copper asset sales. RBC's forecasts for 2026-28 EBITDA and EPS remain stable, projecting H1 EBITDA of $9.8 billion and EPS of $0.23, with marketing earnings expected to outperform consensus. Production estimates include significant outputs in copper, coal, and zinc, and additional capital returns are anticipated, supported by a planned $1 billion Bunge stock sale.
The global autoimmune disease therapeutics market is projected to grow from $80.54 billion in 2025 to $137.85 billion by 2035, at a CAGR of 5.52%. Growth is fueled by rising autoimmune disease prevalence, advances in biologics, JAK inhibitors, monocl...
The Vancouver Chinatown Foundation and RBC are hosting Light Up Chinatown! 2026, a free two-day festival on August 8-9 along Columbia Street in Vancouver’s Chinatown. The event features exclusive food collaborations, live music performances, family a...
New research from iSeatz reveals that U.S. travelers are increasingly strategic about travel rewards programs, with 40% treating them as financial optimization tools and 60% belonging to multiple programs. Despite high enrollment, many travelers find...
BlackRock reported quarterly earnings per share of $13.91, surpassing analyst estimates of $12.69, and revenue of $7.08 billion, exceeding expectations of $6.73 billion. The company’s assets under management reached a record $15.3 trillion, a 22% inc...
A regional nonprofit health plan reduced its Transparency in Coverage machine-readable file (MRF) production time from 45 days to less than 24 hours by integrating TALON's platform directly with its claims administration system. This eliminated a com...
